ZOVIRAX (acyclovir) by Bausch + Lomb is dna polymerase inhibitors [moa]. Approved for herpes simplex virus nucleoside analog dna polymerase inhibitor [epc]. First approved in 1982.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
ZOVIRAX (acyclovir) is a topical ointment containing a nucleoside analog that inhibits herpes simplex virus DNA polymerase. It treats herpes simplex, herpes labialis, genital herpes, and chickenpox by blocking viral DNA replication at the site of infection. The drug has been the cornerstone of topical antiviral therapy since FDA approval in 1982.
Brand team is likely in defensive/transition mode as loss of exclusivity approaches; expect smaller commercial footprint and focus on generic competition management.
DNA Polymerase Inhibitors
Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Bioequivalence Study of Acyclovir 800 mg Tablet in Healthy Thai Volunteers Under Fasting Conditions
Neonatal Phase 1 Valacyclovir Study
A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally
Pharmacokinetic Properties of 200 and 400 mg Acyclovir Tablet in Indonesia Healthy Subject
Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
Worked on ZOVIRAX at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ZOVIRAX offers limited upside for ambitious pharma professionals given its LOE-approaching status and minimal linked job openings. Roles available are primarily in defensive commercial activities—managing generic transition, optimizing pricing, and maintaining market share in a declining market. Career growth potential is constrained by product maturity and competitive erosion.